Hepatitis Drug Market Analyze the Companies, Institutions & Universities Currently Operating In the Pipeline Review, 2017
Orbis Research has announced the addition of the “Hepatitis Drug Development Pipeline Review, 2017” to store by company, by country, and by application/type for the competitive landscape analysis.
Dallas, United States – August 3, 2017 /MarketersMedia/ —
This report provides an overview of the hepatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, B, C and D, and features dormant and discontinued projects.
Browse the complete report @ http://www.orbisresearch.com/reports/index/hepatitis-drug-development-pipeline-review-2017
Hepatitis is a contagious viral infection affecting the liver, which may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting. The predisposing factors of hepatitis typically include dialysis, organ transplant and blood transfusion and the offspring of an infected mother also has high chances of contracting the disease.
Owing to differences in prevalence, hepatitis A and D have far smaller pipelines than hepatitis B and C; the size of these pipelines ranges from seven products in hepatitis A to 182 in hepatitis B and 199 in hepatitis C. Many of the companies who are actively fielding products in the larger two hepatitis subtypes are simultaneously developing products for both. While in hepatitis A, B and D, viral surface antigens and interferons are commonly targeted, a far wider range of proteins, including non-structural proteins, are the most common targets in hepatitis C.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/369959
Scope
– Which companies are the most active within the pipeline for hepatitis therapeutics
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies
– What are the most important R&D milestones and data publications to have happened in the field of hepatitis
Reasons to buy
– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Buy a report @ http://www.orbisresearch.com/contact/purchase/369959
List of Figures
Number of Products under Development for Hepatitis A 13
Number of Products under Development by Companies, Hepatitis A 14
Number of Products under Development by Universities/Institutes, Hepatitis A 15
Number of Products under Development for Hepatitis B 17
Number of Products under Development by Companies, Hepatitis B 18
Number of Products under Development by Universities/Institutes, Hepatitis B 22
Number of Products under Development for Hepatitis C 30
Number of Products under Development by Companies, Hepatitis C 31
Number of Products under Development by Universities/Institutes, Hepatitis C 34
Number of Products under Development for Hepatitis D 43
Number of Products under Development by Companies, Hepatitis D 44
Number of Products by Molecule Types, Hepatitis A 46
Number of Products by Stage and Molecule Types, Hepatitis A 47
Number of Products by Top 10 Targets, Hepatitis B 48
Number of Products by Stage and Top 10 Targets, Hepatitis B 48
Number of Products by Top 10 Mechanism of Actions, Hepatitis B 50
Number of Products by Stage and Top 10 Mechanism of Actions, Hepatitis B 50
Number of Products by Top 10 Routes of Administration, Hepatitis B 52
Number of Products by Stage and Top 10 Routes of Administration, Hepatitis B 52
Number of Products by Top 10 Molecule Types, Hepatitis B 54
Number of Products by Stage and Top 10 Molecule Types, Hepatitis B 54
Number of Products by Top 10 Targets, Hepatitis C 56
Number of Products by Stage and Top 10 Targets, Hepatitis C 56
Number of Products by Top 10 Mechanism of Actions, Hepatitis C 59
Number of Products by Stage and Top 10 Mechanism of Actions, Hepatitis C 59
Number of Products by Routes of Administration, Hepatitis C 62
Number of Products by Stage and Routes of Administration, Hepatitis C 62
Number of Products by Top 10 Molecule Types, Hepatitis C 64
Number of Products by Stage and Top 10 Molecule Types, Hepatitis C 64
Number of Products by Targets, Hepatitis D 65
Number of Products by Stage and Targets, Hepatitis D 66
Number of Products by Mechanism of Actions, Hepatitis D 67
Number of Products by Stage and Mechanism of Actions, Hepatitis D 67
Number of Products by Routes of Administration, Hepatitis D 69
Number of Products by Stage and Routes of Administration, Hepatitis D 69
Number of Products by Molecule Types, Hepatitis D 70
Number of Products by Stage and Molecule Types, Hepatitis D 71
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Info:
Name: Hector Costello
Organization: Orbis Research
Address: 144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A.
Phone: +912064101019
For more information, please visit http://www.orbisresearch.com/reports/index/hepatitis-drug-development-pipeline-review-2017
Source: MarketersMedia
Release ID: 224728
Copyright © 1999-2013 SproutNews.com
